- Home
- RGCO vs SLS Comparison
RGCO vs SLS Comparison
Compare RGCO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGCO | SLS |
|---|---|---|
| Founded | 1912 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.9M | 706.7M |
| IPO Year | 2005 | 2007 |
Fundamental Metrics
Financial Performance| Metric | RGCO | SLS |
|---|---|---|
| Price | $22.74 | $5.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 8.2K | ★ 5.5M |
| Earning Date | 05-07-2026 | 04-16-2026 |
| Dividend Yield | ★ 3.87% | N/A |
| EPS Growth | 11.21 | ★ 62.69 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $95,334,212.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $3.36 | N/A |
| P/E Ratio | $47.96 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.68 | $0.95 |
| 52 Week High | $23.82 | $5.66 |
Technical Indicators
Market Signals| Indicator | RGCO | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 74.63 |
| Support Level | $20.49 | $1.48 |
| Resistance Level | $23.01 | N/A |
| Average True Range (ATR) | 0.57 | 0.50 |
| MACD | 0.12 | 0.13 |
| Stochastic Oscillator | 92.89 | 93.19 |
Price Performance
Historical ComparisonAbout RGCO RGC Resources Inc.
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.